Premium
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-09 | Dr. Keith N. G. BradleyIndependent Director | -882,00 | 12,28k | Sale to Issuer | 13,92 | 88,25k | -0,99% |
| 2026-03-11 | Mr. Harvinder Pal SinghExec. VP & President of International Business | 18,92k | 0,00 | Derivative Exercise and Retained Stock | - | 35,42k | 114,68% |
| 2026-03-10 | Mr. Harvinder Pal SinghExec. VP & President of International Business | -1,22k | 11,65k | Derivative Exercise and Sale | 9,55 - 9,61 | 35,42k | - |
| 2026-03-11 | Mr. Harvinder Pal SinghExec. VP & President of International Business | -5,44k | 52,24k | Sale to Issuer | 9,61 | 35,42k | -13,30% |
| 2026-03-10 | Mr. Robert T. DavisExec. VP & President of Tissue Technologies | -9,17k | 88,12k | Sale to Issuer | 9,55 - 9,61 | 66,39k | -12,14% |
| 2026-03-10 | Mr. Michael J. McBreenChief Commercial Officer | -9,60k | 92,12k | Sale to Issuer | 9,55 - 9,61 | 60,74k | -13,65% |
| 2026-03-10 | Mr. Jeffrey A. MosebrookSenior VP of Finance & Principal Accounting Officer | -1,15k | 11,00k | Sale to Issuer | 9,55 - 9,61 | 35,45k | -3,13% |
| 2026-03-11 | Ms. Lea Daniels KnightExec. VP & CFO | -8,09k | 77,74k | Sale to Issuer | 9,61 | 50,49k | -13,81% |
| 2026-03-11 | Ms. Chantal Veillon-BertelootExec. VP & Chief HR Officer | -5,42k | 52,09k | Sale to Issuer | 9,61 | 22,23k | -19,60% |
| 2026-01-06 | Ms. Mojdeh PoulInitié | -1,39k | 18,25k | Derivative Exercise and Sale | 13,13 | 0,00 | - |
| 2025-11-05 | Dr. Jeffrey Alan GravesIndependent Director | 9,00k | 102,15k | Achat | 11,35 | 41,09k | 28,05% |
| 2025-10-12 | Mr. Harvinder Pal SinghExec. VP & President of International Business | 8,68k | 0,00 | Derivative Exercise and Retained Stock | - | 21,94k | 65,53% |
| 2025-10-12 | Mr. Harvinder Pal SinghExec. VP & President of International Business | -3,28k | 43,77k | Derivative Exercise and Sale | 13,34 | 21,94k | - |
| 2025-09-01 | Ms. Chantal Veillon-BertelootExec. VP & Chief HR Officer | -3,55k | 53,73k | Sale to Issuer | 15,13 | 27,65k | -11,38% |
| 2025-08-14 | Dr. Stuart M. EssigCEO, President & Chairman | -200,00k | 2,72M | Other Disposition | 13,62 | 1,79M | -10,07% |
| 2025-07-03 | Ms. Lea Daniels KnightExec. VP & CFO | -2,56k | 34,55k | Sale to Issuer | 13,49 | 58,58k | -4,19% |
| 2025-07-03 | Mr. Jeffrey A. MosebrookSenior VP of Finance & Principal Accounting Officer | -3,35k | 45,12k | Sale to Issuer | 13,49 | 36,60k | -8,37% |
| 2025-07-01 | Mr. Jeffrey A. MosebrookSenior VP of Finance & Principal Accounting Officer | -937,00 | 12,42k | Sale to Issuer | 13,25 | 39,95k | -2,29% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
